nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.07.2009 | Original Article

Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer’s disease

verfasst von: Sönke Arlt, Stefanie Brassen, Holger Jahn, Florian Wilke, Martin Eichenlaub, Ivayla Apostolova, Fabian Wenzel, Frank Thiele, Stewart Young, Ralph Buchert

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Brain imaging of FDG uptake and cerebrospinal fluid (CSF) concentration of amyloid-beta 1–42 (Aβ_1-42) or tau proteins are promising biomarkers in the diagnosis of Alzheimer’s disease (AD). There is still uncertainty regarding any association between decreased FDG uptake and alterations in CSF markers.

Methods

The relationship between FDG uptake, CSF Aβ_1-42 and total tau (T-tau), as well as the Mini-Mental State Examination (MMSE) score was investigated in 34 subjects with probable AD using step-wise linear regression. FDG uptake was scaled to the pons.

Results

Scaled FDG uptake was significantly reduced in the probable AD subjects compared to 17 controls bilaterally in the precuneus/posterior cingulate area, angular gyrus/inferior parietal cortex, inferior temporal/midtemporal cortex, midfrontal cortex, and left caudate. Voxel-based single-subject analysis of the probable AD subjects at p < 0.001 (uncorrected) revealed a total volume of significant hypometabolism ranging from 0 to 452 ml (median 70 ml). The total hypometabolic volume was negatively correlated with the MMSE score, but it was not correlated with the CSF measures. VOI-based step-wise linear regression revealed that scaled FDG uptake in the precuneus/posterior cingulate was negatively correlated with CSF Aβ_1-42. Scaled FDG uptake in the caudate was positively correlated with CSF T-tau.

Conclusion

The extent and local severity of the reduction in FDG uptake in probable AD subjects are associated with cognitive impairment. In addition, there appears to be a relationship between local FDG uptake and CSF biomarkers which differs between different brain regions.

Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594–607.PubMed

Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094–103.PubMedCrossRef

Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2:605–13.PubMedCrossRef

Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, et al. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008;29:1143–59.PubMedCrossRef

Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652–6.PubMed

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003;60:1696–702.PubMedCrossRef

Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512–9.PubMedCrossRef

Kadekaro M, Crane AM, Sokoloff L. Differential effects of electrical stimulation of sciatic nerve on metabolic activity in spinal cord and dorsal root ganglion in the rat. Proc Natl Acad Sci U S A 1985;82:6010–3.PubMedCrossRef

Mielke R, Schroder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer’s disease. Acta Neuropathol 1996;91:174–9.PubMedCrossRef

10.

Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, et al. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002;59:1267–72.PubMedCrossRef

11.

Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120–7.PubMedCrossRef

12.

Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Itoh M, et al. Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans. Neurosci Lett 1999;273:203–7.PubMedCrossRef

13.

Fellgiebel A, Siessmeier T, Scheurich A, Winterer G, Bartenstein P, Schmidt LG, et al. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 2004;56:279–83.PubMedCrossRef

14.

Mosconi L, De Santi S, Brys M, Tsui WH, Pirraglia E, Glodzik-Sobanska L, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 2008;63:609–18.PubMedCrossRef

15.

Ceravolo R, Borghetti D, Kiferle L, Tognoni G, Giorgetti A, Neglia D, et al. CSF phosphorylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer’s disease. Brain Res Bull 2008;76:80–4.PubMedCrossRef

16.

Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional Imaging: a general linear approach. Hum Brain Mapp 1995;2:189–210.CrossRef

17.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.PubMed

18.

Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920–8.PubMed

19.

Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545–8.PubMed

20.

Wienhard K, Eriksson L, Grootoonk S, Casey M, Pietrzyk U, Heiss WD. Performance evaluation of the positron scanner ECAT EXACT. J Comput Assist Tomogr 1992;16:804–13.PubMedCrossRef

21.

Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995;19:541–7.PubMedCrossRef

22.

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273–89.PubMedCrossRef

23.

Perneger TV. What’s wrong with Bonferroni adjustments. BMJ 1998;316:1236–8.PubMed

24.

Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302–16.PubMedCrossRef

25.

Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48.PubMed

26.

Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer’s disease correlates with progressive metabolic impairment of association areas. Dementia 1994;5:36–41.PubMed

27.

Bouwman FH, van der Flier WM, Schoonenboom NS, van Elk EJ, Kok A, Rijmen F, et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007;69:1006–11.PubMedCrossRef

28.

Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer’s disease determined by dynamic FDG-PET. J Nucl Med 1996;37:201–8.PubMed

29.

Cummings JL. Toward a molecular neuropsychiatry of neurodegenerative diseases. Ann Neurol 2003;54:147–54.PubMedCrossRef

30.

Mendez MF, Perryman KM, Miller BL, Swartz JR, Cummings JL. Compulsive behaviors as presenting symptoms of frontotemporal dementia. J Geriatr Psychiatry Neurol 1997;10:154–7.PubMed

31.

Baxter LR Jr, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry 1987;44:211–8.PubMed

32.

Poldrack RA, Packard MG. Competition among multiple memory systems: converging evidence from animal and human brain studies. Neuropsychologia 2003;41:245–51.PubMedCrossRef

33.

Poldrack RA, Clark J, Pare-Blagoev EJ, Shohamy D, Creso Moyano J, Myers C, et al. Interactive memory systems in the human brain. Nature 2001;414:546–50.PubMedCrossRef

34.

Klimkowicz-Mrowiec A, Slowik A, Krzywoszanski L, Herzog-Krzywoszanska R, Szczudlik A. Severity of explicit memory impairment due to Alzheimer’s disease improves effectiveness of implicit learning. J Neurol 2008;255:502–9.PubMedCrossRef

35.

Andersson J. Re: PET scan reconstructions (item 009521 in SPM mail archive). 2002. https://www.jiscmail.ac.uk/cgi-bin/wa.exe?A2=ind02&L=SPM&P=R174130. Accessed 4 Feb 2009.

36.

Hoffman EJ, Cutler PD, Guerrero TM, Digby WM, Mazziotta JC. Assessment of accuracy of PET utilizing a 3-D phantom to simulate the activity distribution of [18F]fluorodeoxyglucose uptake in the human brain. J Cereb Blood Flow Metab 1991;11:A17–25.PubMed

37.

Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, et al. Statistical brain mapping of 18F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001;42:548–57.PubMed

38.

Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897–916.PubMedCrossRef

39.

Okada J, Yoshikawa K, Imazeki K, Uno K, Minoshima S, Itami J, et al. Change of cerebral glucose metabolism by antineoplastic drug. Am J Physiol Imaging 1991;6:162–6.PubMed

40.

Phillips PC, Dhawan V, Strother SC, Sidtis JJ, Evans AC, Allen JC, et al. Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. Ann Neurol 1987;21:59–63.PubMedCrossRef

Titel: Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer’s disease
verfasst von: Sönke Arlt
Stefanie Brassen
Holger Jahn
Florian Wilke
Martin Eichenlaub
Ivayla Apostolova
Fabian Wenzel
Frank Thiele
Stewart Young
Ralph Buchert
Publikationsdatum: 01.07.2009
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1063-7

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2009

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information

Positron emission tomography in patients suffering from HIV-1 infection

2009 EANM parathyroid guidelines

Effects of medial temporal lobe degeneration on brain perfusion in amnestic MCI of AD type: deafferentation and functional compensation?

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate